RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  04:00 2022-08-17 pm EDT
236.41 USD   +0.32%
11:19aFDA says faulty Philips device reports accelerating as CEO departs
RE
08/17RESMED, INC. : Ex-dividend day for
FA
08/16What do investors want?
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

05/18/2022 | 04:05pm EDT
  • 2–3 hours of nightly PAP use shows health benefits at 3 months, 1 year, and 2 years
  • Health benefits significantly increase by use hour/night, up to 7 hours

SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual International Conference.

The retrospective, observational study analyzed the deidentified usage data of 180,000 U.S. PAP users to observe their average rates of all-cause hospitalization and emergency room visits based on the number of nightly hours they use PAP, from zero to nine. Researchers found:1

  • The minimum PAP usage threshold for benefit was 2-3 hours per night (up to 50% lower than the 4 hours required by the U.S. Centers for Medicare and Medicaid and many private payers to prove adherence)
  • Benefits begin at 2 hours of nightly PAP use and increase each hour up to 7 hours per night. Benefits were seen at 90 days, one year, and two years into the study.
  • Over the two years, each additional hour of nightly PAP use reduced:
    • Hospitalizations by 5.0%
    • ER visits by 4.4%

“This study can positively change how healthcare professionals prescribe and encourage sleep apnea sufferers to use PAP – and how they’re covered,” said Atul Malhotra, lead author and research chief of Pulmonary, Critical Care, and Sleep Medicine at the University of California San Diego.

Today, the U.S. Centers for Medicare and Medicaid define PAP therapy adherence as using a PAP device for at least four hours per night for 70% of nights in a consecutive 30-day period in the first 90 days of therapy.2 Patients who do not achieve adherence may risk losing their machine after 90 days or having to pay for it themselves, depending on their insurance coverage.

“If just two hours of nightly PAP use can significantly lower a patient’s risk of getting hospitalized, our health systems should encourage and enable people to access and keep using these solutions,” Malhotra said.

An estimated 54 million Americans have obstructive sleep apnea,3 a chronic disease in which throat muscles relax during sleep, constricting airflow. The body’s resulting jolt “awake” to take a breath causes dozens to hundreds of sleep interruptions per night. Sufferers often aren’t aware of these waking episodes, and 80% remain undiagnosed.4

Read the study’s full abstract here.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

1 Malhotra A et al. Am J Respir Crit Care Med suppl (ATS Abstract) 2022
2 Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=204. Accessed May 2, 2022.
3 Benjafield AV et al. Lancet Resp Med 2019
4 Young T et al. Sleep 1997

For Media
Kristin Deuber
+1 615.975.4186
resmed@allisonpr.com
For Investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Primary Logo

Source: ResMed Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about RESMED, INC.
11:19aFDA says faulty Philips device reports accelerating as CEO departs
RE
08/17RESMED, INC. : Ex-dividend day for
FA
08/16What do investors want?
MS
08/16ANALYST RECOMMENDATIONS : Visa, Mastercard, ResMed, Extra Space Storage, Equifax...
MS
08/15Morgan Stanley rates RMD as Equal-weight
AQ
08/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/12Illumina, ResMed fall; Broadridge, Humana rise
AQ
08/12INSIDER SELL : Resmed
MT
08/12Morgan Stanley Adjusts Price Target for ResMed to $222 From $204, Maintains Equalweight..
MT
08/12JPMorgan Downgrades ResMed to Neutral From Overweight, Lowers Price Target to $250 From..
MT
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2023 3 989 M - -
Net income 2023 910 M - -
Net Debt 2023 397 M - -
P/E ratio 2023 38,3x
Yield 2023 0,76%
Capitalization 34 616 M 34 616 M -
EV / Sales 2023 8,78x
EV / Sales 2024 7,92x
Nbr of Employees 8 160
Free-Float 77,1%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 236,41 $
Average target price 252,50 $
Spread / Average Target 6,81%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-9.24%34 571
THERMO FISHER SCIENTIFIC-10.67%235 900
DANAHER CORPORATION-9.65%218 583
INTUITIVE SURGICAL, INC.-36.07%83 460
EDWARDS LIFESCIENCES CORPORATION-22.40%63 408
BOSTON SCIENTIFIC CORPORATION-0.12%60 629